Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAK 360

Next Previous
Drug Profile

TAK 360

Alternative Names: TAK-360

Latest Information Update: 08 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Class Sleep disorder therapies; Small molecules
  • Mechanism of Action Orexin receptor type 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Idiopathic hypersomnia; Narcolepsy

Most Recent Events

  • 06 May 2025 Phase-II clinical trials in Narcolepsy in USA (PO) (NCT06952699)
  • 01 May 2025 Takeda plans a phase II trial for Narcolepsy (In adults, In the elderly) in May 2025 (PO) (NCT06952699)
  • 13 Feb 2025 Takeda plans a phase II trial in Idiopathic hypersomnia (PO, Tablet) (NCT06812078)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top